Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework-Reference-Cited by-同舟云学术

Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework

Published:2020-02-20 Issue:5 Volume:22 Page:734-742
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Packer Milton¹²^ORCID

Affiliation:

1. Baylor Heart and Vascular Institute, Baylor University Medical Center Dallas Texas

2. Imperial College London UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13961

Reference99 articles.

1. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

2. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

3. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

4. Liraglutide and Renal Outcomes in Type 2 Diabetes

5. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin-activated AMPK elicits neuroprotective properties in reserpine-induced depression via regulating dynamics of hippocampal autophagy/inflammation and PKCζ-mediated neurogenesis;Psychopharmacology;2024-08-19

2. The potential anti-arrhythmic effect of SGLT2 inhibitors;Cardiovascular Diabetology;2024-07-15

3. The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review;International Journal of Molecular Sciences;2024-06-27

4. Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side;Journal of Clinical Medicine;2024-02-07

5. How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial;Nephrology Dialysis Transplantation;2024-02-06